News >

Expert Discusses Impact of Muscle-Invasive Bladder Cancer Guidelines

Danielle Bucco
Published: Thursday, Aug 24, 2017

Jonathan E. Rosenberg, MD

Jonathan E. Rosenberg, MD
There are now interdisciplinary guidelines for the treatment of patients with muscle-invasive bladder cancer, following a collaboration with the American Urological Association (AUA) and other prominent groups, such as the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), and the Society of Urologic Oncology (SUO).

, Rosenberg, a medical oncologist at Memorial Sloan Kettering Cancer Center, discussed the guidelines and their significance for the treatment of patients with muscle-invasive bladder cancer.

OncLive: Can you discuss these guidelines for bladder cancer and their significance?

Rosenberg: Traditionally, muscle-invasive bladder cancer has been managed purely by urologists in the United States with radical cystectomy being the only treatment often offered. However, there have been several large, randomized trials that show a benefit with cisplatin-based neoadjuvant chemotherapy prior to cystectomy.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: New York Advanced Practice CollaborativeNov 15, 20191.25
Medical Crossfire®: Treating MS in the Modern Era: Right Patient, Right Treatment, Right TimeApr 20, 20201.5
Publication Bottom Border
Border Publication